DiaMedica Q2 Loss Widens to $10.1M; ReMEDy2 Stroke Trial Hits 85% Enrollment, Interim Analysis Set for Q1 2027

summarizeSummary

DiaMedica reported a $10.1M Q2 net loss and disclosed that its ReMEDy2 stroke trial is 85% enrolled toward the interim analysis, now expected in Q1 2027. Cash of $43.5M funds operations for at least 12 months.

check_boxKey Events · Earnings and Guidance · DMAC

• Q2 Net Loss Widens

  Net loss of $10.1M vs $7.7M in Q2 2025, driven by higher R&D spending on ReMEDy2 and preeclampsia programs.

• ReMEDy2 Enrollment at 85%

  The pivotal stroke trial has enrolled 85% of the 200 patients needed for the interim analysis, now expected in Q1 2027. The trial could stop for futility or expand to up to 728 patients.

• Preeclampsia Program Advances

  Phase 2 Part 1a completed; Parts 1b and 2 enrollment expected September/October 2026. U.S. IND still requires rat PK study data (completion October 2026).

• Cash Runway at Least 12 Months

  Cash, equivalents, and marketable securities of $43.5M as of June 30, 2026. No going concern warning, but additional capital will be needed before any product approval.

auto_awesomeAnalysis · DMAC · Life Sciences

DiaMedica's Q2 results show a widening loss as R&D spending ramps for its pivotal ReMEDy2 stroke trial and expanding preeclampsia program. The key update is that ReMEDy2 enrollment has reached 85% of the 200-patient interim analysis target, with that analysis now expected in Q1 2027 — a concrete milestone that could make or break the DM199 stroke program. Cash of $43.5M provides at least 12 months of runway, but the company will need additional capital before any potential approval. The preeclampsia program is advancing with Part 1a completed and Parts 1b/2 starting soon, though U.S. IND remains gated by an ongoing rat PK study. The ATM program has $86.2M remaining, giving the company a ready financing tool but also creating overhang.